The first authorized generic version of Amitiza (lubiprostone; Mallinckrodt) has been made available by Par Pharmaceutical, Inc.
Lubiprostone, a chloride channel activator, is indicated for the treatment of chronic idiopathic constipation, as well as opioid-induced constipation in adult with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation. The drug is also approved to treat irritable bowel syndrome with constipation in women at least 18 years old.
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
For more information visit parpharm.com.
Endo launches authorized generic version of Amitiza® (lubiprostone) capsules in the United States. [press release]. Dublin, Ireland; Endo International plc; January 4, 2021.
This article originally appeared on MPR